CHR Metz-Thionville
Metz, Moselle, 57085, France
NCT Number: NCT03525496
Iodinated contrast agents (ICA) are widely used in medical imaging. They provide however a risk of immediate hypersensitivity reactions (IHS). The risk of anaphylactic shock is estimated at 1/100 000 injections. Nevertheless, for safety reasons and to limit undesirable effects, the reintroduction tests are not conducted along similar lines to throughout scan or arteriography. Moreover, reintroduction protocols are actually not standardized, in terms of injected volume and doses progression. It should be evaluated the relevance of the reintroduction tests with injection of a low volume and ensure the absence of reaction during the ICA injections Under real conditions.
The investigators are assuming that the realization of a provocation test by intravenous reintroduction with a reduced dose of ICA improves the predictive value of IHS in comparison with only cutaneous tests.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Metz, Moselle, 57085, France
The main objective of this study will be to estimate the negative predictive value of the combination of cutaneous tests and provocation test by intravenous reintroduction in the IHS to iodinated contrast agents.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 1
Occurrence of immediate hypersensitivity reactions after an injection of ICA
Centre Hospitalier Régional Metz-Thionville
Other
Acronym: DHIODE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07703982
Allergic Reaction, Hypersensitivity
Birmingham, Alabama, United States
View Trial DetailsNCT06011603
Allergic Reaction, Hypersensitivity
Chicago, Illinois, United States
View Trial DetailsNCT06957496
Allergic Reaction, Allergic Skin Reaction
Madrid, Spain
View Trial DetailsNCT06527937
Allergic Reaction, Hypersensitivity
Secaucus, New Jersey, United States
View Trial Details